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Abstract
Osteoprotegerin (OPG) plays a central role in controlling bone resorption. Exogenous administration of OPG
has been shown to be effective in preventing osteolysis and limiting the growth of osteolytic metastasis. The
objective of this study was to investigate the effects of OPG on osteoblastic prostate cancer (CaP) metastases in
an animal model. LuCaP 23.1 cells were injected intra-tibially and Fc-OPG (6.0 mg/kg) was administered subcu-
taneously three times a week starting either 24 hours prior to cell injection (prevention regimen) or at 4 weeks
post-injection (treatment regimen). Changes in bone mineral density at the tumor site were determined by dual
x-ray absorptiometry. Tumor growth was monitored by evaluating serum prostate specific antigen (PSA). Fc-
OPG did not inhibit establishment of osteoblastic bone lesions of LuCaP 23.1, but it decreased growth of the
tumor cells, as determined by decreases in serum PSA levels of 73.0 ± 44.3% (P < 0.001) and 78.3 ± 25.3%
(P < 0.001) under the treatment and prevention regimens, respectively, compared to the untreated tumor-bear-
ing animals. Administration of Fc-OPG decreased the proliferative index by 35.0% (P ¼ 0.1838) in the treat-
ment group, and 75.2% (P ¼ 0.0358) in the prevention group. The results of this study suggest a potential role
for OPG in the treatment of established osteoblastic CaP bone metastases.
Abbreviations: bone mineral density – BMD; 3,30-diaminobenzidine tetrahydrochloride – DABC; prostate cancer
– CaP; dual x-ray absorptiometry – DEXA; osteoprotegerin – OPG; prostate specific antigen – PSA; receptor
activator of NF-jB – RANK; receptor activator of NF-jB ligand – RANKL
Introduction
A characteristic property of metastatic prostate can-
cer (CaP) is its propensity to colonize and thrive in
skeletal tissue. CaP skeletal metastases are associated
with advanced disease and represent a significant
therapeutic challenge. Skeletal deposits of metastatic
CaP alter the normal physiology of the bone, lead-
ing to disruption of the bone remodeling cycles.
Normal remodeling is marked by the coordinated
activities of bone formation and resorption, which
are essential for the proper function and integrity of
skeletal tissue [1]. CaP disruption of bone remodeling
usually causes a net increase in bone formation lead-
ing to the development of osteoblastic lesions [2, 3];
however, a significant resorptive component is also
observed [4–7]. Release of growth factors from the
mineralized matrix during resorption may facilitate
the initial seeding and growth of tumor cells in the
bone [8]. Many of the proteins involved in these
processes have now been identified, and the altera-
tions in bone remodeling observed in CaP bone
metastases offer an increasingly attractive target for
therapeutic intervention.
A key molecular system that influences bone remod-
eling consists of receptor activator of NF-jB ligand
(RANKL), receptor activator of NF-jB (RANK), and
osteoprotegerin (OPG). OPG is a member of the tumor
necrosis factor receptor superfamily that functions as a
decoy receptor for RANKL. Association of RANKL
with OPG prevents it from interacting with its cognate
receptor, RANK. An increase in the ratio of OPG to
RANKL inhibits the recruitment, activation and sur-
vival of osteoclasts and results in increased bone
mass. Transgenic mice overexpressing OPG exhibit an
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osteopetrotic phenotype [9], while OPG-knockout mice
have severe osteoporosis [10, 11]. Thus the OPG/
RANKL ratio is an important element in the control
of normal bone remodeling.
The RANKL/RANK/OPG system is also involved
in various pathologies associated with metastatic dis-
ease in bone [12]. An elevated RANKL/OPG ratio is
observed in osteolytic malignancies such as breast can-
cer and multiple myeloma [13–17] and we have
recently reported increased expression of RANKL in
CaP bone metastases [18]. Treatment with Fc-OPG in
certain mouse models diminishes growth and osteolytic
lesions of myeloma and breast cancer cells in bone [17,
19]. In prostate cancer, Fc-OPG administration
decreased the establishment and subsequent intra-osse-
ous growth of C4-2B CaP cells, which stimulate osteo-
clast formation in vitro [20], and LNCaP cells, which
give rise to mixed osteoblastic/osteolytic lesions [21].
These results suggest that osteoclast activation may
play an important role in promoting the initial growth
of CaP in the bone environment.
In this study we have used the CaP xenograft
LuCaP 23.1, which induces production of new bone,
resulting in sclerotic lesions in murine models. Admin-
istration of Fc-OPG inhibited the growth of LuCaP
23.1 xenograft in the bone, but did not alter the estab-
lishment of skeletal lesions. The results suggest poten-
tial benefits of OPG in the treatment of patients with
established osteoblastic CaP bone metastases.
Methods
Animal studies
All animal experiments were performed in compliance
with the University of Washington Institutional Ani-
mal Care and Use Committee and NIH guidelines.
The LuCaP 23.1 xenograft was established in our labo-
ratory from a pelvic lymph node metastasis [22, 23]. It
elicits a robust osteoblastic reaction in bone [24]. Sin-
gle-cell suspensions of LuCaP 23.1 cells were used for
direct intra-tibial injections as we have previously
described [24].
Thirty-six-week-old Fox Chase SCID male mice
(Charles River, Wilmington, Massachusetts) were
injected with 1)2 · 105 cells into the right tibiae. The
animals were then randomized into three groups: 1) a
control group (n ¼ 10); 2) a treatment group (n ¼
10), with Fc-OPG injections beginning 4 weeks after
xenograft injections; and 3) a prevention group (n ¼
10), with Fc-OPG injections beginning 24 h prior to
injection of tumor cells. The Fc-OPG used in this
study contains the ligand-binding domain of human
OPG fused to the Fc domain of human IgG [9, 19].
Fc-OPG (6.0 mg/kg) was administered subcutaneously
three times a week; the control group received injec-
tions of vehicle (PBS). Tumor burden was monitored
during the study by measuring serum levels of prostate
specific antigen (PSA). Determination of serum PSA
was performed weekly starting at day 16 (IMx Total
PSA Immunoassay, Abbot Laboratories, Abbott Park,
Illinois). Mice were sacrificed 8 weeks after the xeno-
graft injection. The time of sacrifice was assigned
based on serum PSA levels of the control group and
the radiographical appearance of the tumored tibiae
(indicating mid-stage LuCaP 23.1 osseous tumors).
Prior to sacrifice, all mice were radiographed with a
diagnostic mammography unit (LoRad, Danbury,
Connecticut) with the following settings: 35 kv,
2.3 sec, 20.7 mA/sec. Both tumor-bearing and contra-
lateral tibiae were harvested for bone mineral density
(BMD) determinations. Tumor-bearing tibiae were
then processed for immunohistochemical analysis.
Bone densitometry
BMD was measured using dual-energy X-ray absorpti-
ometry (DEXA) on an Eclipse peripheral DEXA Scan-
ner (Norland, Ft. Atkinson, Wisconsin). Data analysis
was performed with software provided by the com-
pany. The region of interest (2.5 mm · 2.5 mm)
encompassed the tumor injection site and was located
2.0 mm from the proximal end of the tibiae. Excised
tibiae were placed laterally on the scanner for analysis.
Scanning was done at 2 mm/s with a resolution of
0.1 mm · 0.1 mm. Short-term BMD precision (%
coefficient of variation) was less than 3% for this tech-
nique.
Immunohistochemistry
Tibiae with LuCaP 23.1 tumors were processed for his-
tology and immunohistochemistry by fixation in 10%
neutral buffered formalin for 24 hours. After fixation,
tibiae were decalcified in 10% EDTA for two consecu-
tive 48-hour periods and embedded in paraffin. 5.0-lm
longitudinal sections were used for staining. Histologi-
cal verification of intra-tibial tumors was assessed by
hematoxylin and eosin (H&E) staining. Tibial sections
were also examined immunohistochemically for expres-
sion of PSA and human Ki-67. Briefly, sections were
deparaffinized, rehydrated, and incubated for 10 min
at room temperature in 3% H2O2 in methanol to
block endogenous peroxidase activity. Specimens were
blocked for one hour in a cocktail of 5% horse, 5%
goat, and 5% chicken serum in 1 PBS. The sections
for Ki-67 staining underwent antigen retrieval in 1
citrate buffer (pH 6.0) for 10 min. Detection of PSA
was performed using a rabbit polyclonal anti-PSA
antibody (DAKO, Carpinteria, California), diluted in
blocking cocktail, at a concentration of 3 lg/ml for
one hour at room temperature. A rabbit polyclonal
anit-Ki-67 (DAKO) was used at a dilution of 1:50.
Normal rabbit IgG (DAKO) served as the negative
control. After incubation of primary antibodies and
subsequent washing, sections were stained with bioti-
nylated goat anti-rabbit IgG (DAKO) at a dilution of
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1:150 in blocking cocktail for one hour at room tem-
perature. Immunoreactiviy was detected with the Vec-
tastain Elite ABC kit (Vector Laboratories,
Burlingame, California) and color-developed with 3,30-
diaminobenzidine tetrahydrochloride (DABC). The
proliferative index was determined by counting Ki-67-
positive nuclei. In every sample, three representative
40x-fields were scored for positive tumor nuclei (85
nuclei on average; control group and prevention group
n ¼ 3 animals, treatment group n ¼ 2 animals).
Statistical analysis
Statistical analysis was performed using GraphPad
Prism (GraphPad Software, Inc., San Diego, Califor-
nia). Significance of the differences between the groups
was determined using a two-tailed Student’s t-test.
Association between PSA levels and proliferative index
was evaluated using the Pearson correlation.
Results
LuCaP 23.1 xenograft grew in the tibiae of SCID male
mice and yielded an osteoblastic reaction. Skeletal
LuCaP 23.1 lesions were established in 100% of the
animals in the control and prevention groups and 90%
in the treatment group. Three mice from the control
group, two from the treatment group, and one mouse
from the prevention group were excluded from analy-
sis due to compromised integrity of the tibial shaft
resulting from tumor delivery, and subsequent growth
of tumor in muscle. One mouse in the prevention
group expired during the study and was excluded from
subsequent analysis. Evidence of increased bone mass
is observed in the x-rays of the tumor-bearing tibiae
(Figure 1A). A large volume of new trabecular bone
mass was observed in tumor-bearing tibiae of all three
groups, but it was most noticeable in the prevention
and treatment groups (Figure 1). Tumor foci were
present in the tibia in all three groups; however, in the
groups that received Fc-OPG, tumor foci decreased in
size (Figure 1).
Bone mineral density
Representative examples of DEXA scans and the
effects of Fc-OPG administration on the BMD of Lu-
CaP 23.1-containing and contralateral non-tumor-
bearing tibiae are shown in Figure 2. In accordance
with its osteoblastic character, LuCaP 23.1 caused sig-
nificant increases in BMD over the contralateral non-
tumor-bearing tibiae (P ¼ 0.0004) of the control
group. Fc-OPG administration in the treatment group
tumor-bearing tibiae did not significantly alter BMD
vs LuCaP 23.1-bearing tibiae of the control group
(P ¼ 0.2767), but longer administration (8 weeks) of
Fc-OPG in the prevention group increased BMD
Figure 1. Representative photomicrographs of LuCaP 23.1 bone metastases with and without administration of Fc-OPG. Tibiae of SCID mice
were injected with LuCaP 23.1 cells and Fc-OPG was administered under prevention and treatment regimens as described in Methods. (A)
Representative radiographs of LuCaP 23.1 tumors in tibiae. Radiographs were taken using a mammography unit. LuCaP 23.1 cells caused a
strong osteoblastic reaction in the bone in all three groups (control, prevention, treatment) as indicated by arrow. The tibiae containing tumor are
wider and denser, as represented by whiter color in the radiographs. Spiking of outgrowing bone caused by the tumor is seen in the upper right
and lower portions of the preventive-group tibia. In the portion between these spikes the original cortical shaft has been conserved. (B)
Representative histology of LuCaP 23.1 tumors in tibiae. Five-micrometer sections of decalcified LuCaP 23.1 tibiae were stained with hematoxilin
& eosin. Tumor foci (designated by a T) are observed in samples from all three groups. Large trabecular bone mass is observed in all groups. (C)
Represenative PSA staining of LuCaP 23.1 tumors in tibiae. Five-micrometer sections of decalcified LuCaP 23.1 tibiae were stained with anti-
PSA antibody. PSA-positive cells were detected in tibiae from all three groups. Intensive PSA immunoreactivity is observed in tumors from all
three groups.
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Figure 2. Effects of Fc-OPG on bone mineral density of tibiae with osteoblastic LuCaP 23.1 metastases. (a) Representative examples of DEXA
scans of LuCaP 23.1 bone metastases with or without Fc-OPG administration: (a) control group, (b) prevention group, (c) treatment group.
Yellow color indicates areas of high BMD. The xenograft injection site is marked by yellow box. (d) BMD was measured at the site of injection of
tumor cells as described in Methods. Results were normalized to non-tumor-bearing tibiae of untreated animals, and are presented as
mean ± SEM. Significant increases of BMD were observed in the control group tumor-bearing tibiae vs contralateral non-tumored tibiae (P¼
0.0004). Administration of Fc-OPG caused additional increases in BMD of LuCaP 23.1 tibiae (treatment: P < 0.0001, prevention: P < 0.0001)
when compared to non-tumor bearing contralateral tibia. Fc-OPG administration under both regimens also caused increases in BMD in non-
tumor bearing tibiae vs. control non-tumored tibiae (treatment: P¼0.0081, prevention: P¼0.0026). LuCaP 23.1 causes an osteoblastic reaction in
the bone; therefore one may expect that a smaller tumor burden should result in decreased BMD. However, since OPG is a negative regulator of
bone lysis, administration of Fc-OPG also causes increases in BMD. (There are two opposing effects of Fc-OPG on BMD: inhibition of tumor
growth, which tends to reduce BMD, and inhibition of osteolysis, which increases BMD.) Since we have shown that Fc-OPG inhibits prolif-
eration of LuCaP 23.1 in bone, we attributed the increases in BMD to inhibition of osteolysis by Fc-OPG. The significance of the differences was
determined by the Student’s t-test.
Figure 3. (a) Effects of Fc-OPG on serum PSA levels in animals bearing LuCaP 23.1 bone metastases. Blood samples were drawn from animals
with LuCaP 23.1 bone metastases weekly starting at day 16 after injection of the tumor cells. PSA levels were determined by IMx Total PSA
assay; mean ± SEM is plotted against time post-injection. Significant decreases in serum levels of PSA were detected at day 57 in both
prevention (78.3 ± 25.3% decrease, P < 0.001) and treatment (73.0 ± 44.3% decrease, P < 0.001) groups vs control group. (b) Effects of
Fc-OPG on proliferation of LuCaP 23.1 cells in the bone environment. Five-micrometer sections of decalcified LuCaP 23.1 tibiae were stained
with anti-Ki-67 antibody. Representative examples of Ki67 immunoreactivity and analysis of the results are presented. Data were normalized to
control group and are shown as a percent decrease in positive nuclei. A decrease in the proliferation index of 35.0% (P¼ 0.1838) in the treatment
group, and 75.2% (P ¼ 0.0358) was detected in the prevention group.
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significantly (P ¼ 0.0393) over the BMD of the Lu-
CaP 23.1 tibiae of the control group. Fc-OPG admin-
istration under both regimens significantly increased
BMD in non-tumor-bearing tibiae (P ¼ 0.0081, P ¼
0.0026; prevention and treatment, respectively). LuCaP
23.1 causes an osteoblastic reaction in the bone; there-
fore a smaller tumor burden should lead to lower
osteoblast activity and decreased BMD. However,
since OPG is a negative regulator of bone lysis,
administration of Fc-OPG also causes an increase in
BMD. There are two opposing effects of Fc-OPG on
BMD – inhibition of tumor growth, which tends to
reduce BMD, and inhibition of osteolysis, which
increases BMD. Since we have shown that Fc-OPG
inhibits proliferation of LuCaP 23.1 in bone, we attri-
bute an observed increase in BMD in the prevention
group vs the control to the second effect of Fc-OPG,
inhibition of osteolysis.
Serum PSA levels
To monitor tumor burden in the tibiae, serum PSA lev-
els were measured in animals bearing LuCaP 23.1.
There was a trend toward reduced serum PSA levels in
the prevention and treatment groups, compared to the
control group, over the course of the study (Figure 3A).
At day 56 post-injection, there were significant
decreases in PSA levels in both treatment (73.0 ±
44.3%, P < 0.001) and prevention (78.3 ± 25.3%,
P < 0.001) groups vs control group. Serum PSA levels
are used to detect CaP and monitor the response of the
disease to the treatment. However, in some cases serum
PSA levels in patients are not always representative of
the tumor burden, since various factors present in bone
(e.g., IL-6) can affect PSA expression. We have previ-
ously shown that the tumor volume of LuCaP 23.1 is
correlated with serum PSA levels in animals bearing Lu-
CaP 23.1 subcutaneous tumors as well as tumors in ti-
biae [22–25]. Therefore in the present study we conclude
that significantly lower levels of PSA in serum of treated
animals suggest decreased tumor burden of osteoblastic
LuCaP 23.1 in bone.
Proliferation index
Reduced serum PSA levels in animals treated with
Fc-OPG suggest a relative reduction in tumor bur-
den [24, 25]. We measured the proliferation index of
the LuCaP 23.1 xenografts in tibiae to determine
whether reduced PSA levels were associated with a
decrease in proliferation of tumor cells in tibiae. Fc-
OPG administration under both regimens decreased
the proliferative index of LuCaP 23.1 in tibiae (Fig-
ure 3b). The proliferation index of LuCaP 23.1
decreased by 35.0% (P ¼ 0.1838) in the treatment
group and 75.2% (P ¼ 0.0358) in the prevention
group. A significant correlation was observed
between the proliferative index and serum PSA level
(Pearson r ¼ 0.771, P ¼ 0.0254).
Discussion
The majority of CaP bone metastases exhibit osteo-
blastic characteristics, and animal models that pos-
sess this trait are therefore of special interest for the
study of human disease. However, despite the overall
osteoblastic appearance of many CaP bone metasta-
ses, an osteolytic component is frequently evident
within these lesions. It has been hypothesized that
the increased rates of bone-formation and -resorption
cycles associated with CaP metastases may promote
skeletal metastases [11, 26]. These observations and
ideas give rise to the paradox that osteoblastic CaP
metastases may be successfully treated by inhibition
of osteolysis. In the present study we have sought to
investigate this hypothesis by administering the anti-
resorptive molecule OPG to the LuCaP 23.1 osteo-
blastic xenograft injected into the tibiae of SCID
mice.
Administration of Fc-OPG attenuated LuCaP 23.1
skeletal tumor growth, as indicated by reduced serum
PSA levels and a decreased LuCaP 23.1 proliferation
index. These observations suggest that normal and/or
pathological bone resorption may promote the growth
of LuCaP 23.1 cells in bone, and that inhibition of
osteolysis blocks or attenuates the growth process. We
have reported previously [25] that LuCaP 23.1 in the
bone environment causes a decrease in the number of
osteoclasts vs normal tibia. We have also shown
separately that administration of the osteolysis-inhibit-
ing compounds zoledronic acid [25] and Fc-OPG (our
unpublished data) causes a trend toward further
decreases in osteoclast numbers in the LuCaP 23.1
model of bone metastasis; however, because LuCaP
23.1 itself inhibits osteoclast formation, the cell num-
bers involved are very small even without the treat-
ment, and these further decreases generally do not
achieve statistical significance.
Inhibition of bone resorption by OPG may also
lead to a reduction in available growth-promoting
substances liberated from the bone matrix by osteo-
clast. It is possible that reduction in bone lysis with
Fc-OPG treatment reduced the growth of tumor cells
by mechanisms related to inhibition of osteolysis.
However, another therapeutic mechanism of action
might involve direct effects of Fc-OPG on tumor
cells. Work from other laboratories [11, 19] indicates
that Fc-OPG fails to inhibit the growth of various
tumor cells in vitro. This is not surprising, as there
are no known signaling receptors for OPG. Never-
theless, OPG may affect tumor cells by blocking
RANKL-mediated signals. Cells of the osteoclast
lineage, along with breast epithelium and dendritic
cells, respond to RANKL signaling, leading to differ-
entiation and survival [27], and inhibition of this sig-
naling pathway may slow the growth of CaP cells
directly. Experimental confirmation of this hypothesis
is not possible with the LuCaP 23.1 xenograft
because it does not grow in vitro.
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In contrast to the observed inhibition of growth
of LuCaP 23.1 bone metastases, the rate of estab-
lishment of LuCaP 23.1 in the bone was not altered
by administration of Fc-OPG. Similarly, we have
reported previously that zoledronic acid, another
anti-resorptive compound, did not affect the
establishment of LuCaP 23.1 growth in the tibia
[25]. Lee et al. also failed to observe inhibitory
effects of zoledronic acid on tumor establishment of
the osteoblastic CaP xenograft LAPC9 in bone [28].
These results contrast with those of an earlier study
in which Fc-OPG inhibited the establishment of C4-
2B in the tibiae of SCID mice. The particular
properties of the tumor models used in the studies
may affect the results. In the present study we have
used the LuCaP 23.1 xenograft, which yields
osteoblastic lesions [24]. Zhang et al. used C4-2B
cells [20], and Yonou et al. used LNCaP [21], both
of which result in mixed lytic/blastic lesions. As with
C4-2B, Fc-OPG administration has been shown to
inhibit establishment of lytic bone metastases of my-
leoma and breast [17, 19]. Therefore stimulation of
osteolysis by tumor cells appears to be a critical fac-
tor in the colonization of bone by tumors that exhi-
bit mixed or osteolytic phenotypes.
Previous animal studies have shown that treat-
ment with Fc-OPG results in a generalized increase
in overall bone density [9]. Administration of Fc-
OPG for four weeks did not significantly change the
BMD of the tumor-bearing tibiae under the treat-
ment regimen vs the untreated LuCaP 23.1 tibiae,
although it did significantly increase the BMD in the
treated non-tumor-bearing tibiae vs the control non-
tumor-bearing tibiae. The observed decrease in serum
PSA levels and proliferative rate indicates a lower
tumor burden in the treatment group. One would
therefore expect lower levels of BMD vs the control
untreated tumor-bearing tibiae. We hypothesize that
the administration of Fc-OPG, in conjunction with
an initial LuCaP 23.1 growth period, increased the
BMD of the tumored tibiae vs non-tumor-bearing
tibiae of the control group.
In conclusion, our results show that administration
of Fc-OPG attenuated the growth of the LuCaP 23.1
tumor in the bone environment as determined by
serum PSA levels and decreased proliferative index,
but it did not inhibit the initial establishment of Lu-
CaP 23.1 osteoblastic bone metastases. While results
of this study do not delineate the mechanisms of
growth inhibition of osseous CaP metastasis by OPG,
they indicate the potential value of employing exoge-
nous Fc-OPG in combination with other therapeutics
in the treatment of established CaP-osseous metastasis.
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